Most patients with a cardiac resynchronisation therapy (CRT) pacemaker would not benefit from the addition of a defibrillator, according to results from the CeRtiTuDe cohort study presented for the ...

San Francisco, CA - Heart-failure patients with implanted cardiac resynchronization therapy (CRT) devices are more likely to die if they aren't also taking beta blockers, mostly due to an increased ...

Certain groups of heart failure patients may see improved heart function with cardiac resynchronization therapy with defibrillator (CRT-D) if traditional implantable cardioverter defibrillator ...

Shanghai, China - The first patient implants of the Boston Scientific Corporation COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) were successfully performed in China’s Zhejiang ...

The results of COMPANION also demonstrate that CRT or CRT-D, in combination with optimal pharmacologic therapy (OPT), each respectively reduced the rate of death or hospitalization from any cause by ...

Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable ...

Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable ...

Medtronic CRT-D Devices Demonstrate Survival Benefits for Mildly Symptomatic Heart Failure Patients in Two Pivotal Clinical Trials MINNEAPOLIS – Medtronic, Inc. today announced that the U.S. Food and ...

DUBLIN, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE (Conformité Européenne) Mark for its Cobalt™ and Crome™ portfolio of implantable ...

Defibrillators, with or without cardiac resynchronization therapy, can reduce the rate of sudden death. However, shocks are unpleasant, often unnecessary, and can damage myocardium or defibrillator ...

The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...